Sanofi, Re­gen­eron build their case for yet an­oth­er ap­proval for im­munol­o­gy star Dupix­ent

Over the week­end Sanofi and Re­gen­eron post­ed an­oth­er up­beat round of da­ta from their Phase III pro­gram for the pow­er­house Dupix­ent — this time in eosinophilic esophagi­tis. And they made it clear that they’ll be us­ing the re­sults to hunt yet an­oth­er reg­u­la­to­ry nod for the mega block­buster fran­chise this year.

Re­searchers for the part­ners turned out at the 2022 AAAAI an­nu­al meet­ing to tout a 64% re­duc­tion in dis­ease symp­toms from base­line com­pared to 41% for place­bo. They added:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER